MustGrow Biologics Corp. (MGRO.V)
CAD 1.24
(-3.13%)
CAD 1.24
(-3.13%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -294.76 Thousand | -3.25 Million | -2.41 Million | -2.57 Million | -1.35 Million | -968.34 Thousand |
| Net Income | -676.94 Thousand | -5.56 Million | -3.06 Million | -3.3 Million | -1.51 Million | -1.89 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 926.42 Thousand | 1.69 Million | 270.81 Thousand | 776.9 Thousand | 124.78 Thousand | 112.86 Thousand |
| Change in working capital | -544.24 Thousand | 603.69 Thousand | 328.52 Thousand | 13.52 Thousand | -5136.00 | -114.06 Thousand |
| Other non-cash items | 833.99 Thousand | 10.06 Thousand | 52.76 Thousand | -59.32 Thousand | 45.87 Thousand | 926.22 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | 4.00 | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 95.75 Thousand | 653.75 Thousand | 8.71 Million | 1.86 Million | 4.87 Million | 1.46 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 95.75 Thousand | 653.75 Thousand | 6.58 Million | 1.86 Million | 4.8 Million | 1.46 Million |
| Other Financing Activities | 95.75 Thousand | - | 2.13 Million | 36 Thousand | 68.9 Thousand | 4990.00 |
| Accounts receivables | -7022.00 | -23.49 Thousand | -31.02 Thousand | -12.99 Thousand | 5540.00 | -19.59 Thousand |
| Accounts payables | 99.45 Thousand | -273.78 Thousand | 351.24 Thousand | 44.92 Thousand | -4232.00 | -124.95 Thousand |
| Inventory | - | 297.27 Thousand | - | - | - | - |
| Other working capital | -641.2 Thousand | 603.69 Thousand | 8299.00 | -18.4 Thousand | -6444.00 | -114.06 Thousand |
| Cash at beginning of period | 7.01 Million | 9.61 Million | 3.31 Million | 4.02 Million | 507.32 Thousand | 7156.00 |
| Cash at end of period | 6.81 Million | 7.01 Million | 9.61 Million | 3.31 Million | 4.02 Million | 507.32 Thousand |
| Capital Expenditure | 4.00 | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -199.01 Thousand | -2.6 Million | 6.3 Million | -716.01 Thousand | 3.52 Million | 500.17 Thousand |
| Free Cash Flow | -294.76 Thousand | -3.25 Million | -2.41 Million | -2.57 Million | -1.35 Million | -968.34 Thousand |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -960.2 Thousand | -1.03 Million | 3.43 Million | -676.94 Thousand | -1.85 Million | -1.2 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 12.67 Thousand | 144.15 Thousand | -290.59 Thousand | 926.42 Thousand | 1.01 Million | 77.25 Thousand |
| Change in working capital | -26.4 Thousand | -40.99 Thousand | -489.62 Thousand | -544.24 Thousand | -91.12 Thousand | 23.5 Thousand |
| Other non-cash items | 15.43 Thousand | 193.02 Thousand | -395.96 Thousand | 833.99 Thousand | 1.12 Million | 97.89 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | 1.00 | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | -241.34 Thousand | - | - | 95.75 Thousand | 95.75 Thousand | - |
| Debt repayment | -241.34 Thousand | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | 95.75 Thousand | 95.75 Thousand | - |
| Other Financing Activities | -241.34 Thousand | - | - | - | - | - |
| Accounts receivables | -56.31 Thousand | -29.42 Thousand | 3899.00 | -7022.00 | 9803.00 | -24.74 Thousand |
| Accounts payables | 53.56 Thousand | -19.45 Thousand | 101.46 Thousand | 99.45 Thousand | -118.21 Thousand | 4104.00 |
| Inventory | -30.12 Thousand | - | - | - | - | - |
| Other working capital | 6479.00 | 7877.00 | -594.98 Thousand | -641.2 Thousand | 17.28 Thousand | 44.14 Thousand |
| Cash at beginning of period | 5.88 Million | 6.81 Million | 4.16 Million | 7.01 Million | 5 Million | 6.1 Million |
| Cash at end of period | 4.67 Million | 5.88 Million | 6.81 Million | 6.81 Million | 4.16 Million | 5 Million |
| Capital Expenditure | 1.00 | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -1.21 Million | -931.37 Thousand | 2.65 Million | -199.01 Thousand | -836.51 Thousand | -1.1 Million |
| Free Cash Flow | -973.93 Thousand | -931.37 Thousand | 2.65 Million | -294.76 Thousand | -932.25 Thousand | -1.1 Million |
ALRGR
EXPLEOSOL
SOFW
000755
7096
HUBG